About us

Xspray Pharma AB (publ) is a pharmaceutical company with multiple product candidates in clinical development. Xspray Pharma uses its innovative, patented HyNap technology to develop improved versions of marketed protein kinase inhibitors (PKIs), known as original drugs, for the treatment of cancer. The segment is the largest in the field of oncology, and drug prices are extremely high.

PKIs revolutionized the treatment of cancer when they entered the market more than 20 years ago, and there are now over 80 approved PKIs in the US market. Despite their clinical advantages, they are associated with problems such as low solubility, high variability in uptake and impact on uptake in conjunction with the ingestion of food and other drugs. These properties negatively impact patients’ quality of life and can result in a less efficacious treatment. Xspray Pharma’s business strategy is to improve these properties using the company’s technology, and develop best-in-class drug products.

The company’s first product candidate, Dasynoc®, is nearing commercialization. The product candidate is ready for launch in the US market in direct conjunction with approval by the FDA, which is expected in 2025.

Dasynoc’s profile advantages:
• Dasynoc® is unaffected by the pH value of the stomach and can thus be used together with proton-pump inhibitors such as omeprazole without impacting the absorption of the drug. This facilitates concurrent treatment of common diseases in the stomach, such as peptic ulcers and gastritis, with proton-pump inhibitors while the patient is being treated for cancer.
• Dasynoc® yields a more even uptake of the drug in the body without the variations seen in earlier studies of the original product.
• Dasynoc® can be administered at a 30-percent lower dose than the original product.

Moreover, Xspray is conducting specific clinical studies to demonstrate the advantages of the product candidates in relation to the original product and its generics.